Dr. Trudy A Yavorek, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 900 Washington Rd, Kach - Attn Chc, West Point, NY 10996 Phone: 845-938-3003 Fax: 845-938-5777 |
Dr. Anthony Douglas Hirtz, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 900 Washington Rd, Credential's Office, Keller Army Community Hospital, West Point, NY 10996 Phone: 845-938-4114 |
News Archive
Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
A compact microscope invented at Rice University is proving its potential to impact global health. In a paper published online today in the journal PLoS ONE, Rice alumnus Andrew Miller and co-authors show that his portable, battery-operated fluorescence microscope, which costs $240, stacks up nicely against devices that retail for as much as $40,000 in diagnosing signs of tuberculosis.
Many drug-resistant infections are the result of bacterial biofilms, structured aggregates of bacteria that live on surfaces and that are extremely resistant to environmental stresses. These biofilms impact human health in many ways - cystic fibrosis, for example, is a disease in which patients die from airway bacterial biofilm infections that are invulnerable to even the most potent antibiotics.
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.
› Verified 8 days ago